Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.
Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial